Journal of the American Academy of Child & Adolescent Psychiatry
New researchFamily-Based Genome-Wide Association Scan of Attention-Deficit/Hyperactivity Disorder
Section snippets
Subjects
Families were ascertained at Massachusetts General Hospital (MGH; N = 309 trios), Washington University at St Louis (WASH-U; N = 272 trios), and University of California at Los Angeles (UCLA; N = 156 trios). Children were 6 to 17 years of age at initial assessment and met criteria for DSM-IV-TR ADHD. All study procedures were reviewed and approved by the subcommittee for human subjects of each respective institution. All subjects' parents or guardians signed written informed consent forms and
Results
After applying quality control filters, association with ADHD was tested with 835,136 SNPs in 735 DSM-IV-TR ADHD trios from 732 families; clinical demographics of the sample are presented in Table 2. Subjects recruited at WASH-U were older (p < .001) and more likely to be diagnosed with predominantly inattentive ADHD (p < .001) compared with both the MGH and the UCLA samples. Subjects recruited at UCLA were less likely to be Caucasian compared with both the MGH and WASH-U samples (p < .001).
Discussion
We failed to identify any statistically significant genome-wide findings, but we found some additional evidence for a role of SLC9A9 in the etiology of ADHD. SLC9A9 codes a hydrogen/sodium exchanger located in the membranes of subcellular structures and is expressed in the brain, heart and skeletal muscle, placenta, kidney, and liver.18 SLC9A9 was first identified at a break point in a family in which ADHD symptoms were correlated with a chromosome 3 inversion.18 It was also associated with
References (29)
- et al.
Genetics of attention deficit hyperactivity disorder
Child Adolesc Psychiatr Clin North Am
(2008) - et al.
Discrimination of DSM-IV and latent class attention-deficit/hyperactivity disorder subtypes by educational and cognitive performance in a population-based sample of child and adolescent twins
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Reliability and stability of a semistructured DSM-IV interview designed for family studies
J Am Acad Child Adolesc Psychiatry
(2003) - et al.
Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit/hyperactivity disorder
J Am Acad Child Adolesc Psychiatry
(2000) - et al.
PLINK: a tool set for whole-genome association and population-based linkage analyses
Am J Hum Genet
(2007) - et al.
Molecular genetics of attention deficit hyperactivity disorder
Biol Psychiatry
(2005) - et al.
Meta-analysis of genomewide linkage scans of attention deficit hyperactivity disorder
Am J Med Genet B Neuropsychiatr Genet
(2008) - et al.
The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes
Mol Psychiatry
(2006) - et al.
Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies
J Neural Transm
(2008) - et al.
Genome-wide association scan of attention deficit hyperactivity disorder
Am J Med Genet B Neuropsychiatr Genet
(2008)
Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations
Am J Med Genet B Neuropsychiatr Genet
Estimation of prevalence of DSM-IV and latent class-defined ADHD subtypes in a population-based sample of child and adolescent twins
Twin Res Hum Genet
High-throughput variation detection and genotyping using microarrays
Genome Res
Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms
Hum Hered
Cited by (0)
This article was reviewed under and accepted by Ad Hoc Editor James F. Leckman, M.D.
Genotyping was conducted by Genizon BioSciences Inc. with the financial support of Pfizer Inc. Subject ascertainment and assessment was supported by the following sources: National Institutes of Health (NIH) grants R13MH059126, R01MH62873, U01MH085518 and R01MH081803 to S.V.Faraone; National Institute of Neurological Disorders and Stroke (NINDS) grant NS054124 S. Loo; National Institute of Mental Health (NIMH) grant MH01966 to J. McGough; National Institute on Drug Abuse (NIDA) grant K24 DA016264 to T. Wilens; NIMH grant MH63706 to S. Smalley; and NIMH grants K08MH001503 and R01MH066237 to J. Wozniak.
This article is one of several articles published in the August and September issues of the Journal of the American Academy of Child and Adolescent Psychiatry that explores the intersection of genetics and mental health disorders in children and adolescents. The editors invite the reader to investigate the additional articles on this burgeoning area of developmental psychopathology.
Disclosure: Dr. Mick receives research support from Ortho-McNeil Janssen Scientific Affairs, Pfizer, Shire Pharmaceuticals, and has served on the advisory board for Shire Pharmaceuticals.
Dr. Biederman receives research support from Alza, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merck, Organon, Otsuka, Shire, the National Institute of Mental Health (NIMH), and the National Institute of Child Health and Human Development (NICHD). He has served on the speakers' bureau for Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, Dr. Biederman received research support, consultation fees, or speaker's fees for/from Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Janssen, McNeil, NARSAD, National Institute on Drug Abuse (NIDA), New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc., and Wyeth.
Dr. McCracken has received research support from Bristol-Myers Squibb, Aspect, and Seaside Pharmaceuticals. He has served as a consultant to Novopharm and BioMarin, and has received speaker honoraria from the Tourette Syndrome Association, Veritas, and CME Outfitters.
Dr. McGough has served as a consultant to and received research support and consulting honoraria from Eli Lilly and Co. and Shire Pharmaceuticals.
Dr. Wilens has received grant support from Abbott, McNeil, Eli Lilly and Co., the National Institutes of Health (NIH), the National Institute on Drug Abuse (NIDA), Merck, and Shire. He has served on the speakers' bureaus for Eli Lilly and Co., McNeil, Novartis, and Shire. He has served as a consultant for Abbott, AstraZeneca, McNeil, Eli Lilly and Co., the NIH/NIDA, Novartis, Merck, and Shire. Dr. Wilens receives royalties from Guilford Press for his book, Straight Talk About Psychiatric Medications for Kids.
Dr. Wozniak receives royalties from Bantam Books for her book, Is Your Child Bipolar? Dr. Wozniak has served on the speakers' bureau for McNeil, Primedia/Massachusetts General Hospital (MGH), Psychiatry Academy, and Eli Lilly and Co. Dr. Wozniak is on the advisory board and has served as a consultant for Pfizer and Shire. She receives research support from McNeil, Shire, and Eli Lilly and Co.
Dr. Faraone has, in the past year, received consulting fees and has been on advisory boards for Eli Lilly and Co., Ortho-McNeil and Shire Development and has received research support from Eli Lilly and Co., Pfizer, Shire and the National Institutes of Health. In previous years, Dr. Faraone has received consulting fees or has been on Advisory Boards or has been a speaker for Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly and Co. In previous years he has received research support from Eli Lilly and Co., Shire, Pfizer, and the National Institutes of Health.
Drs. Todorov, Smalley, Hu, Loo, Todd (deceased), Dechairo, Nelson, Reiersen, Neale, and Ms. Byrne, and Mr. Guiney report no biomedical financial interests or potential conflicts of interest.
This article is discussed in an editorial by Drs. James J. Hudziak and Stephen V. Faraone on page 729 of the August 2010 issue.
Supplemental material cited in this article is available online.